$0.04 EPS Expected for Wright Medical Group N.V. (WMGI); Cognex (CGNX) Had 8 Bulls

February 21, 2018 - By mmahotstuff

Analysts expect Wright Medical Group N.V. (NASDAQ:WMGI) to report $0.04 EPS on February, 27 after the close.They anticipate $0.10 EPS change or 166.67% from last quarter’s $-0.06 EPS. WMGI’s profit would be $4.18 million giving it 126.00 P/E if the $0.04 EPS is correct. After having $-0.16 EPS previously, Wright Medical Group N.V.’s analysts see -125.00% EPS growth. The stock increased 0.50% or $0.1 during the last trading session, reaching $20.16. About 953,464 shares traded. Wright Medical Group N.V. (NASDAQ:WMGI) has risen 49.62% since February 21, 2017 and is uptrending. It has outperformed by 32.92% the S&P500.

Among 19 analysts covering Cognex Corporation (NASDAQ:CGNX), 8 have Buy rating, 2 Sell and 9 Hold. Therefore 42% are positive. Cognex Corporation had 38 analyst reports since August 4, 2015 according to SRatingsIntel. On Friday, December 8 the stock rating was upgraded by Daiwa Securities to “Buy”. The firm earned “Hold” rating on Tuesday, October 31 by Canaccord Genuity. The firm has “Outperform” rating given on Friday, January 22 by Raymond James. The firm has “Mkt Perform” rating by FBR Capital given on Wednesday, November 11. The firm earned “Buy” rating on Wednesday, November 18 by Canaccord Genuity. The firm has “Buy” rating given on Friday, September 8 by Cowen & Co. FBR Capital initiated Cognex Corporation (NASDAQ:CGNX) rating on Wednesday, May 11. FBR Capital has “Market Perform” rating and $42 target. The stock has “Hold” rating by Canaccord Genuity on Tuesday, August 4. The firm has “Buy” rating by Cowen & Co given on Tuesday, February 13. The stock has “Buy” rating by Needham on Friday, February 17. See Cognex Corporation (NASDAQ:CGNX) latest ratings:

15/02/2018 Broker: Canaccord Genuity Rating: Hold New Target: $57.0 Maintain
13/02/2018 Broker: Cowen & Co Rating: Buy New Target: $70.0 Maintain
19/01/2018 Broker: Deutsche Bank Rating: Buy New Target: $80.0
08/12/2017 Broker: Daiwa Securities Old Rating: Outperform New Rating: Buy Upgrade
08/11/2017 Broker: J.P. Morgan Rating: Sell New Target: $125.0 Downgrade
31/10/2017 Broker: Canaccord Genuity Rating: Hold Old Target: $95 New Target: $120 Maintain
31/10/2017 Broker: Robert W. Baird Rating: Neutral Old Target: $100 New Target: $124 Maintain
08/09/2017 Broker: Cowen & Co Rating: Buy New Target: $135.0 Maintain

The stock increased 1.20% or $0.67 during the last trading session, reaching $56.44. About 3.75M shares traded or 91.84% up from the average. Cognex Corporation (NASDAQ:CGNX) has risen 131.00% since February 21, 2017 and is uptrending. It has outperformed by 114.30% the S&P500.

Cognex Corporation provides machine vision products that capture and analyze visual information in order to automate tasks primarily in manufacturing processes worldwide. The company has market cap of $9.80 billion. The firm offers machine vision products, which are used to automate the manufacturing and tracking of discrete items, such as mobile phones, aspirin bottles, and automobile tires by locating, identifying, inspecting, and measuring them during the manufacturing or distribution process. It has a 41.59 P/E ratio. The Company’s products include VisionPro, a software suite that provides various vision tools for programming; displacement sensors with vision software for use in 3D application; In-Sight vision systems that perform various vision tasks, including part location, identification, measurement, assembly verification, and robotic guidance; In-Sight vision sensors; ID products, which are used for reading codes that are applied on discrete items during the manufacturing process, as well as have applications in logistics automation for package sorting and distribution; DataMan barcode readers; barcode verifiers; vision-enabled mobile terminals for industrial barcode reading applications; and barcode scanning software development kits.

Investors sentiment decreased to 1.05 in 2017 Q3. Its down 0.28, from 1.33 in 2017Q2. It dived, as 23 investors sold Cognex Corporation shares while 135 reduced holdings. 55 funds opened positions while 111 raised stakes. 72.84 million shares or 2.02% less from 74.34 million shares in 2017Q2 were reported. Pacad Inv holds 0.09% or 3,800 shares in its portfolio. The Illinois-based Rmb Capital Mngmt Limited Liability Corp has invested 0.03% in Cognex Corporation (NASDAQ:CGNX). California Public Employees Retirement Systems has 217,817 shares. Wealthtrust stated it has 0.03% in Cognex Corporation (NASDAQ:CGNX). Brinker Capital reported 0.08% of its portfolio in Cognex Corporation (NASDAQ:CGNX). Texas Permanent School Fund stated it has 63,201 shares. Whittier Of Nevada reported 1,010 shares. Copeland Cap Mgmt Limited Liability Corporation stated it has 30,010 shares. Fincl Bank Of Montreal Can accumulated 75,133 shares or 0.01% of the stock. Private Advisor, a New Jersey-based fund reported 1,836 shares. 500 are owned by Tradewinds Cap Mgmt Llc. The Massachusetts-based Winslow Evans & Crocker has invested 0.16% in Cognex Corporation (NASDAQ:CGNX). Bluestein R H & Comm owns 4,500 shares for 0.03% of their portfolio. 107,773 were accumulated by Great West Life Assurance Can. Allen Inv Management Ltd Limited Liability Company has 21,040 shares for 0.11% of their portfolio.

Since August 25, 2017, it had 0 insider purchases, and 2 sales for $1.30 million activity. The insider Willett Robert sold $849,597. $745,529 worth of Cognex Corporation (NASDAQ:CGNX) shares were sold by J BRUCE ROBINSON. ALIAS PATRICK sold $556,565 worth of stock.

Wright Medical Group N.V., a medical device company, designs, makes, markets, and sells extremities and biologics products.in the United States, Europe, the Middle East, Africa, and internationally. The company has market cap of $2.11 billion. The firm offers joint implants and bone fixation devices for the shoulder, elbow, wrist, hand, foot, and ankle; and biologics products that are used for supporting the treatment of damaged or diseased bones, tendons, and soft tissues, as well as to stimulate bone growth. It currently has negative earnings. It also provides sports medicines and other products to mechanically repair tissue-to-tissue or tissue-to-bone injuries.

- Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.

By

Free Email Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our FREE daily email newsletter:


>